60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Up 40.4% in June

Posted by Jessica Moore on Jul 1st, 2024

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP – Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 323,400 shares, an increase of 40.4% from the May 31st total of 230,400 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average trading volume of 472,400 shares, the days-to-cover ratio is presently 0.7 days.

60 Degrees Pharmaceuticals Trading Down 2.7 %

SXTP traded down $0.01 on Monday, reaching $0.25. The stock had a trading volume of 96,970 shares, compared to its average volume of 412,981. 60 Degrees Pharmaceuticals has a 12-month low of $0.20 and a 12-month high of $8.65. The business’s 50-day moving average price is $0.26 and its two-hundred day moving average price is $0.42. The company has a market cap of $3.00 million and a P/E ratio of -0.24.

60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.19. The company had revenue of $0.08 million for the quarter. As a group, analysts predict that 60 Degrees Pharmaceuticals will post -0.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Thursday, June 6th.

Get Our Latest Report on 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Company Profile

(Get Free Report)

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.